Introduction
Human Papillomaviruses (HPVs) that comprise a large genus belonging to the Papillomaviridae, is a non enveloped virus with a circular double stranded DNA (ds DNA) genome approximately 7.9 kb in size. The genome encodes 6 early genes (E1, E2, E4, E5, E6, and E7) and 2 late genes (L1 and L2). L1 is the major of viral capsid that targeted at a conserved region is used for phylogenetic classification and molecular diagnosis. It has more than 100 subtypes that are capable of infecting the epithelial cells. Depending on the oncogenic potential, its genotypes are categorized into High Risk (HR) and Low Risk (LR) groups. HPVs can cause a variety of clinical manifestations such as warts, anogenital malignancies, cervical cancer and etc. Cervical cancer is the third most common cancer in women worldwide (Laudadido, 2013; Shayanfar et al., 2013) . Globally, cervical cancer accounts for more than 529,000 new cancer cases and more than 275,000 cancer deaths in women annually (Jemal et al., , Narges Izadimood 4 , Kayhan Azadmanesh 5 , Marjan Rahnamaye-Farzami 6 * 2011), with more than 80% of these cases occurring in developing countries . Different methods are available for the HPVs screening, detection and genotyping such as cytologic evaluations (e.g. Pap Tests), PCR Hybridizations, PCR and Real Time PCR. HPV vaccination with cervical cancer screening (via both cytology and HPV molecular assays) can be effective in preventing cervical cancer and decrease its mortality (Jemal et al., 2011; de Freitas et al., 2012; Adams and Carnright, 2013) . Based on the data reported by WHO, the crude incidence and mortality rates of HPV related cervical cancer until 2010 in Iran are about 1.8 and 0.8 per 100,000 per year, respectively. HPVs 16(HR), 18(HR), 31(HR), 6(LR), 11(LR), 33(HR) are the most common HPV genotypes in Iranian women with and without cervical dysplasia. Comparing the alternate national cancer registry reports in Iran shows a slow increase in rate of cervical cancer in country and health authorities have a great concern to conduct country wide programs for estimating the latest prevalence of HPV infection in general population (WHO, 2010) . In parallel, there is an increasing request for HPV detection and genotyping by clinicians that has led to considerable rise in new introduced commercial and in-house molecular assays for HPV diagnosis. Regarding the above mentioned explanation access to accurate diagnostic methods with a reasonable cost is a necessity in Iran as developing country. This survey was conducted to design and develop a HPV genotyping assay by In-House Multiplex Real Time PCR in Iran. The quality and performance of developed assay is assessed based on an evaluation protocol provided in national reference laboratory. 
Materials and Methods

Patients' Specimens
HPVs standard plasmids
HPV DNA Plasmids for fifteen genotypes: 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 , 68 containing partial length L1 sequence (20 e10 4 copy/ µl) were provided and synthesized separately by TIB MOLBIOL ® ,Germany, to be used for preparing standard samples necessary for evaluation studies.
Extraction of HPV DNA
Viral DNA from Thin Prep preservatives and 20-30 mg FFPE specimens was extracted using the QIAamp DNA Mini kit and QIAamp DNA FFPE Tissue kit (Qiagen, Germany), according to the manufacturer's instructions.
Design of primers and probes
We developed and designed 15 set of specific primers and TaqMan probes on the partial region of L1 HPV genotypes sequences by AlleleID 7.5 software. All of sequences comprehensive aligned by Mega5 software and blasted in NCBI database (www.ncbi.nlm.nih.gov/ nucleotide). Analysis of extensive bioinformatics was done on primers and probes designed by Oligo7, Primer Express, Generunner, CLC Main Workbench 5 software's and internet online sites. So, β globin endogenous gene as internal control primers and probe were considered in Multiplex Real Time PCR for ruling out possible PCR inhibition and quality of extracted DNA.
In-house multiplex real time PCR for HPV genotyping
We used 6-FAM, Yakima Yellow, Cy5, Texas Red as fluorescent reporter dye at the 5'end and BHQ-1, BHQ-2 as quencher dye at the 3' end of probes sequences. For the multiplexing, four reaction mixtures were designed: Mix1 (HPV16, 18, 31, 45), Mix2 (HPV 6, 11, 52, 68), Mix3 (β globin, HPV 56,58,59) and Mix4 (HPV 33, 35, 39, 51) . The Multiplex Real Time PCR amplifications were carried out in a 25µl reaction volume containing 12.5µl 2X Premix ExTaq (Probe qPCR)(TaKaRa, Japan), 10pmol/ µl each primers and probes (TIB MOLBIOL, Germany), and 5 µl DNA extracted. These reaction mixtures were amplified in a Rotor Gene 6000 (Corbett Life Science), by using the following conditions: 95ºC; 90s for initial enzyme activation, for 50 cycles 95ºC; 5s, and 60ºC; 60s (with fluorescence detection in Green, Yellow, Red, Orange Channels). Furthermore, all of the four mixtures were tested against known positive specimens of HBV, HCV, HSV1 and 2, VZV, BKV, CMV, Streptococcus pneumonia, Klebsiella pneumonia and Ecoli to evaluate the specificity of primers and probes. Four-fold serial dilutions of HPV plasmids were prepared from 1 to 1000 copy/ µl as separated and mixed samples.
Results
Analytical sensitivity, specificity and accuracy
The quality and performance of developed assay was evaluated focusing on analytical sensitivity (detection limit), specificity and accuracy.
Analytical specificity: the extracted genome of HBV, HCV, HSV1 and 2, VZV, BKV, CMV, Streptococcus pneumonia, Klebsiella pneumonia and Ecoli, 10 HPV negative and 20 HPV positive samples (both as single specimens and mixed cocktails with different copy numbers of each genotype per micro liter from 1 to 1000) were selected. There was no non specific amplification signal in all samples.
Analytical sensitivity: 20 HPV positive samples (15 high risks and low risks HPV genotypes) were tested and only one sample (genotype 52) was falsely negative.
Detection limit: serial dilutions of HPV plasmids were prepared (from 1 to 1000 copy /µl) and the assay could detect 5 copy/µl of each HPV genotypes in single and mixed cocktails. Data for these evaluations are not shown.
Standard curves obtained from HPV plasmids serial dilutions in HPV Mix 1 to HPV Mix 4 showing dynamic ranges from 10 Copies/µl to 1000 Copies/µl are indicated in Figure 1 . HPV 16, 18 (13/105 (12.4%) were the prevalent combination genotypes. We also participated in 2013 WHO HPV LabNet proficiency study with our developed assay. The panel of specimens in this program consists of different single and mixed cocktails of HPV plasmids containing HPV genotypes 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 , 66 and 68b. To be considered as proficient in this program, the assay shall detect 50 International Units (IU)/5 µl of HPV 16 and HPV 18 DNA, and 500 genome equivalents (GE)/5 µl of the other HPV types included in the panel both in samples contains single and multiple plasmids and no more than one false positive result is accepted. Accordingly, our data set using the In-House Multiplex Real Time PCR genotyping assay is recognized as proficient for detection of HPV 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 , 66 and 68b with no false positive result.
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Discussion
To identify HPV genotypes in positive samples detected in cervical screening (i.e., Pap tests), molecular based methods are the most common tests and they can differentiate various high and low risk genotypes. Real Time PCR is one of the revolutionized molecular diagnostic methods that is used as a routine diagnostic assay for rapid detection and genotyping of clinical samples.
In-House Multiplex Real Time PCR designed in present study which is composed of 15 pairs specific primers and 15 TaqMan probes and 1 pairs primers and 1 probe for β globin as internal control can detect 5 copy/5 µl of HPV 6,11(Low Risks), 16, 18, 31, 45, 51, 52, 56, 58, 59, 68 (High Risks) in quadruplex reactions. On the other hand, the validation of method was also confirmed according to results of 2013 WHO proficiency testing program. Our developed assay has high sensitivity (95%), specificity (100%), a wide dynamic linear range (detection limit is 5 Copy/µl) and a high degree of repeatability (at least three times). No evidence of cross-reactivity with other various HPV genotypes and microorganisms was observed. According to estimated price of each test (~$20), it seems that the assay developed in our research is an affordable method in comparison to other commercial kits in Iran. Rapid, reliable results and the capability of simultaneous detection of 15 common HPV genotypes are other advantages of developed assay considering other available commercial technologies. Determination of the different human Papillomavirus genotypes prevalence in women with cervical precancerous and cancer can help to plan and implement national immunization program and also treatment protocols. In our study, HPV genotypes were detected in 105 from 112 samples (93.7 %) and HPV18 (69/61.6%), HPV16 (48/42.9%), HPV58 (18/16.1%), HPV68 (16/14.3%), HPV31 (15/13.4%), HPV 52 (15/13.4%), HPV 59 (14/12.5%), HPV11 (13/11.6%), HPV35 (12/10.7%), HPV56 (11/9.8%), HPV6(9/8%), HPV39 (6/5.4%), HPV45 (4/3.6%), HPV 33 (3/2.7%) and HPV 51 (2/1.8%) were the most common genotypes, respectively. HPV 16, 18 (12.4%) were the most common genotypes in mixed infection. This finding is almost similar to studies that have been performed during the last decade in different regions of Iran and other countries such as Brazil, Turkey, Canada, Kuwait, Germany, New Zealand, India, Saudi Arabia, Malaysia, China and Thailand (Hamkar et al., 2002; Zandi et al., 2010; Allameh et al., 2011; Shahsiah et al., 2011; Eghbali et al., 2012; Kim et al., 2012; Yuce et al., 2012; Afshar et al., 2013; Akcali et al., 2013; Al-Awadhi et al., 2013; Das et al., 2013; Hamzi Abdul Raub et al., 2013; Natphopsuk et al., 2013; Petry et al., 2013; Rocha et al., 2013; Severini et al., 2013; Simonella et al., 2013; Turki et al., 2013; Wang et al., 2013) . Considerable prevalence of HPV genotypes 58, 68, 59, 31 and 11 (more than 10%), suggest that epidemiological evolution of other HPV genotypes in cervical cancer and other cancers associated with papillomaviruses should be considered. As mentioned above comparing the results of these studies represent that HPV genotypes especially HPV 16 ,18 are the most common genotypes in full spectrum of cervical dysplasia's from Cervical Intraepithelial Neoplasia I to invasive squamous cell carcinoma in different age groups especially women with 30-50 years (Clifford et al., 2005; Lee et al., 2011; Kasamatsu et al., 2012; Manjari and Sweta, 2012; Panjgoro et al., 2013; Othman and Othman, 2014) . It is proposed that according to numerous studies in worldwide, screening assays such as pap tests as a single test in screening strategies can't be helpful (Jones et al., 2011; Gichki et al., 2012; Saxena et al., 2012; Heidegger et al., 2013; Junyangdikul et al., 2013) .
In Conclusions, It seems that molecular methods e.g. PCR and Real Time PCR as high throughput, reliable methods with capability of fast detection and genotyping must be developed and used in combination of pap smear in order to proper screening and diagnosis in women with cervical epithelial lesions. Certainly, reliable results obtained from valid diagnostic methods have an important role in selecting best national policies particularly for immunization and prophylactic programs.
